Document Detail

Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations.
MedLine Citation:
PMID:  16157739     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Chronic, hypointense black holes (BHs) are recognized as a sign of permanent damage in patients with multiple sclerosis. Although the effects of interferon beta-1b in reducing the formation of new BHs are established, it is not clear whether the drug may reduce BH duration after these lesions are formed. OBJECTIVE: To analyze the effects of interferon beta-1b in reducing the duration of T1 BHs in patients with multiple sclerosis. DESIGN: Patients were clinically assessed and imaged monthly over a 36-month natural history phase and 36-month therapy phase. Numbers of contrast-enhanced lesions and newly formed BHs were counted on each scan. Each BH was counted until it was no longer seen. SETTING: Outpatient service of the Neuroimmunology Branch at the National Institutes of Health, Bethesda, Md. PATIENTS: Six patients with relapsing-remitting multiple sclerosis were included. One patient did not form any BHs during the therapy phase. Analyses were performed on the remaining 5 individuals. INTERVENTIONS: Interferon beta-1b at the dosage of 8 million international units every other day. MAIN OUTCOME MEASURES: Number and duration (in months) of newly formed BHs. RESULTS: Rate of BH accumulation decreased with treatment (P = .01), but Kaplan-Meier models revealed that the duration of BHs did not shorten (chi2(1) = 2.47, P = .12). CONCLUSIONS: Interferon beta-1b reduces the frequency of new BH formation but does not appear to decrease their duration in time. Analyses with larger patient cohorts are needed to confirm these preliminary findings.
Francesca Bagnato; Shiva Gupta; Nancy D Richert; Roger D Stone; Joan M Ohayon; Joseph A Frank; Henry F McFarland
Related Documents :
20669349 - Relation of uric acid levels to aortic root dilatation in hypertensive patients with an...
3587739 - Modulation of the long-latency reflex to stretch by the supplementary motor area in hum...
11079539 - Nbi-5788, an altered mbp83-99 peptide, induces a t-helper 2-like immune response in mul...
6746319 - Gluten antibodies in patients with multiple sclerosis.
19545329 - Brugada-like changes in the peripheral leads during diagnostic ajmaline test in patient...
18677639 - Employment in multiple sclerosis. exiting and re-entering the work force.
3391629 - Acute mcpp intoxication: report of two cases.
18375639 - Survey of amanita phalloides poisoning: clinical findings and follow-up evaluation.
11369379 - Clinical and specular microscopic manifestations of iridocorneal endothelial syndrome.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article     Date:  2005-09-12
Journal Detail:
Title:  Archives of neurology     Volume:  62     ISSN:  0003-9942     ISO Abbreviation:  Arch. Neurol.     Publication Date:  2005 Nov 
Date Detail:
Created Date:  2005-11-15     Completed Date:  2005-12-15     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0372436     Medline TA:  Arch Neurol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1684-8     Citation Subset:  AIM; IM    
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1400, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adjuvants, Immunologic / therapeutic use*
Brain / drug effects*,  pathology*
Chi-Square Distribution
Interferon-beta / therapeutic use*
Longitudinal Studies
Magnetic Resonance Imaging / methods
Multiple Sclerosis / drug therapy*,  pathology*
Retrospective Studies
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Adjuvants, Immunologic; 145155-23-3/interferon beta-1b; 77238-31-4/Interferon-beta
Comment In:
Arch Neurol. 2005 Nov;62(11):1666-8   [PMID:  16286537 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Canadian Pediatric Asthma Consensus guidelines, 2003 (updated to December 2004): introduction.
Next Document:  Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for ...